Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free ONCY Stock Alerts

Oncolytics Biotech (ONCY) Competitors

Oncolytics Biotech logo
$0.92 -0.01 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 -0.02 (-1.97%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ONCY vs. KMDA, CADL, VALN, LRMR, and AURA

Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Kamada (KMDA), Candel Therapeutics (CADL), Valneva (VALN), Larimar Therapeutics (LRMR), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.

How does Oncolytics Biotech compare to Kamada?

Kamada (NASDAQ:KMDA) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Kamada currently has a consensus target price of $13.00, suggesting a potential upside of 58.34%. Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 828.96%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Kamada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kamada
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Oncolytics Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Kamada has a net margin of 11.19% compared to Oncolytics Biotech's net margin of 0.00%. Kamada's return on equity of 7.72% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Kamada11.19% 7.72% 5.39%
Oncolytics Biotech N/A -2,185.97%-243.94%

20.4% of Kamada shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Oncolytics Biotech had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Oncolytics Biotech and 1 mentions for Kamada. Kamada's average media sentiment score of 0.94 beat Oncolytics Biotech's score of 0.45 indicating that Kamada is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kamada
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncolytics Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kamada has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Kamada has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kamada$180.46M2.62$20.20M$0.3523.46
Oncolytics BiotechN/AN/A-$28.76M-$0.29N/A

Summary

Kamada beats Oncolytics Biotech on 11 of the 15 factors compared between the two stocks.

How does Oncolytics Biotech compare to Candel Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Oncolytics Biotech presently has a consensus price target of $8.50, suggesting a potential upside of 828.96%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 134.68%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Candel Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Candel Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44

Candel Therapeutics' return on equity of -51.44% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A -2,185.97% -243.94%
Candel Therapeutics N/A -51.44%-36.31%

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Candel Therapeutics had 5 more articles in the media than Oncolytics Biotech. MarketBeat recorded 8 mentions for Candel Therapeutics and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.45 beat Candel Therapeutics' score of -0.05 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncolytics Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Candel Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Oncolytics Biotech has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-$28.76M-$0.29N/A
Candel TherapeuticsN/AN/A-$38.18M-$0.71N/A

Summary

Oncolytics Biotech beats Candel Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to Valneva?

Oncolytics Biotech (NASDAQ:ONCY) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Oncolytics Biotech has a net margin of 0.00% compared to Valneva's net margin of -67.64%. Valneva's return on equity of -76.81% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A -2,185.97% -243.94%
Valneva -67.64%-76.81%-26.33%

Oncolytics Biotech presently has a consensus price target of $8.50, suggesting a potential upside of 828.96%. Valneva has a consensus price target of $11.98, suggesting a potential upside of 126.37%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Valneva
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Valneva had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.45 beat Valneva's score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncolytics Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Valneva
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncolytics Biotech has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Oncolytics Biotech has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-$28.76M-$0.29N/A
Valneva$197.56M2.31-$130.33M-$1.58N/A

Summary

Valneva beats Oncolytics Biotech on 8 of the 15 factors compared between the two stocks.

How does Oncolytics Biotech compare to Larimar Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Larimar Therapeutics' return on equity of -137.70% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A -2,185.97% -243.94%
Larimar Therapeutics N/A -137.70%-101.43%

Oncolytics Biotech presently has a consensus price target of $8.50, suggesting a potential upside of 828.96%. Larimar Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 311.47%. Given Oncolytics Biotech's higher probable upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10

In the previous week, Larimar Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Larimar Therapeutics and 3 mentions for Oncolytics Biotech. Larimar Therapeutics' average media sentiment score of 0.66 beat Oncolytics Biotech's score of 0.45 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncolytics Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Larimar Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncolytics Biotech has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-$28.76M-$0.29N/A
Larimar TherapeuticsN/AN/A-$165.67M-$2.21N/A

Summary

Larimar Therapeutics beats Oncolytics Biotech on 9 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to Aura Biosciences?

Oncolytics Biotech (NASDAQ:ONCY) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aura Biosciences is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-$28.76M-$0.29N/A
Aura BiosciencesN/AN/A-$106.19M-$1.79N/A

Aura Biosciences' return on equity of -71.25% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A -2,185.97% -243.94%
Aura Biosciences N/A -71.25%-59.06%

Oncolytics Biotech has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Oncolytics Biotech presently has a consensus price target of $8.50, suggesting a potential upside of 828.96%. Aura Biosciences has a consensus price target of $21.50, suggesting a potential upside of 141.57%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Oncolytics Biotech is more favorable than Aura Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Aura Biosciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Aura Biosciences had 17 more articles in the media than Oncolytics Biotech. MarketBeat recorded 20 mentions for Aura Biosciences and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.45 beat Aura Biosciences' score of 0.32 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncolytics Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aura Biosciences
4 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Oncolytics Biotech beats Aura Biosciences on 7 of the 13 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCY vs. The Competition

Export
MetricOncolytics BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$107.72M$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / SalesN/A157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book-22.887.039.676.67
Net Income-$28.76M$23.62M$3.55B$332.64M
7 Day Performance1.62%3.67%1.70%2.01%
1 Month Performance-4.72%7.17%5.62%9.19%
1 Year Performance67.89%67.04%34.42%39.59%

Oncolytics Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCY
Oncolytics Biotech
2.9706 of 5 stars		$0.92
-1.4%		$8.50
+829.0%		N/A$107.72MN/AN/A30
KMDA
Kamada
4.9105 of 5 stars		$8.20
-1.0%		$13.00
+58.5%		N/A$476.14M$180.46M23.43360
CADL
Candel Therapeutics
3.1175 of 5 stars		$6.29
-3.2%		$18.00
+186.2%		N/A$476.11MN/AN/A60
VALN
Valneva
2.3021 of 5 stars		$5.49
-0.2%		$11.98
+118.1%		N/A$473.59M$197.56MN/A700
LRMR
Larimar Therapeutics
4.065 of 5 stars		$4.44
-2.2%		$16.50
+271.6%		N/A$471.63MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel